He Bin, Xu Bo, Xu Xiaoxing, Li Lixia, Ren Rongrong, Chen Zhiyu, Xiao Jian, Wang Yingwei, Xu Bin
Department of Anesthesiology and SICU, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China.
Department of Epidemiology, Shanghai Jiaotong University, School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China.
Crit Care. 2015 Mar 19;19(1):92. doi: 10.1186/s13054-015-0833-9.
Use of hydroxyethyl starch (HES) in septic patients is reported to increase the mortality and incidence of renal replacement therapy (RRT). However, whether or not use of HES would induce the same result in non-septic patients in the intensive care unit (ICU) remains unclear. The objective of this meta-analysis was to evaluate 6% HES versus other fluids for non-septic ICU patients.
Randomized controlled trials (RCTs) were searched from Pubmed, OvidSP, Embase database and Cochrane Library, published before November, 2013. A meta-analysis was made on the effect of 6% HES versus other fluids for non-septic ICU patients, including mortality, RRT incidence, bleeding volume, red blood cell (RBC) transfusion and fluid application for non-septic patients in ICU.
Twenty-two RCTs were included, involving 6,064 non-septic ICU patients. Compared with the other fluids, 6% HES was not associated with decreased overall mortality (RR = 1.03, 95%CI: 0.09 to 1.17; P = 0.67; I(2) = 0). There was no significant difference in RRT incidence, bleeding volume and red blood cell transfusion between 6% HES group and the other fluid groups. However, patients in HES group received less total intravenous fluids than those receiving crystalloids during the first day in ICU (SMD = -0.84; 95%CI: -1.39 to -0.30; P = 0.003, I(2) = 74%).
This meta-analysis found no increased mortality, RRT incidence, bleeding volumes or RBC transfusion in non-septic ICU patients, but the sample sizes were small and the studies generally were of poor quality.
据报道,脓毒症患者使用羟乙基淀粉(HES)会增加死亡率和肾脏替代治疗(RRT)的发生率。然而,在重症监护病房(ICU)的非脓毒症患者中使用HES是否会导致相同结果仍不清楚。本荟萃分析的目的是评估6% HES与其他液体用于非脓毒症ICU患者的情况。
检索2013年11月之前发表在PubMed、OvidSP、Embase数据库和Cochrane图书馆的随机对照试验(RCT)。对6% HES与其他液体用于非脓毒症ICU患者的效果进行荟萃分析,包括死亡率、RRT发生率、出血量、红细胞(RBC)输注以及ICU中非脓毒症患者的液体应用情况。
纳入22项RCT,涉及6064例非脓毒症ICU患者。与其他液体相比,6% HES与总体死亡率降低无关(RR = 1.03,95%CI:0.09至1.17;P = 0.67;I² = 0)。6% HES组与其他液体组在RRT发生率、出血量和红细胞输注方面无显著差异。然而,在ICU的第一天,HES组患者接受的总静脉输液量少于接受晶体液的患者(SMD = -0.84;95%CI:-1.39至-0.30;P = 0.003,I² = 74%)。
本荟萃分析发现,非脓毒症ICU患者的死亡率、RRT发生率、出血量或红细胞输注没有增加,但样本量较小且研究质量普遍较差。